- Home
- NABL vs CVAC Comparison
NABL vs CVAC Comparison
Compare NABL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NABL | CVAC |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NABL | CVAC |
|---|---|---|
| Price | $7.39 | $5.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $9.31 | $6.83 |
| AVG Volume (30 Days) | 932.0K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | N/A | ★ 0.94 |
| Revenue | ★ $497,665,000.00 | $83,000,117.00 |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $8.97 | $23.40 |
| P/E Ratio | ★ N/A | $5.50 |
| Revenue Growth | ★ 8.65 | N/A |
| 52 Week Low | $6.07 | $2.48 |
| 52 Week High | $10.50 | $5.72 |
Technical Indicators
Market Signals| Indicator | NABL | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 47.09 | 42.38 |
| Support Level | $7.11 | $5.11 |
| Resistance Level | $7.44 | $5.23 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 68.03 | 29.17 |
Price Performance
Historical ComparisonAbout NABL N-able Inc.
N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.